Development and in Vitro Studies of Epidermal Growth Factor−Dextran Conjugates for Boron Neutron Capture Therapy
- 1 January 1996
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 7 (5) , 584-591
- https://doi.org/10.1021/bc9600473
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapyRadiotherapy and Oncology, 1994
- Internalization and excretion of epidermal growth factor‐dextran‐associated radioactivity in cultured human squamous‐carcinoma cellsInternational Journal of Cancer, 1994
- New carborane-based compounds for boron neutron capture therapyAnti-Cancer Drugs, 1994
- Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cellsJournal of Neuro-Oncology, 1992
- Effects of131I-EGF on cultured human glioma cellsJournal of Neuro-Oncology, 1990
- Gene Amplification in Malignant Human Gliomas: Clinical and Histopathologic AspectsJournal of Neuropathology and Experimental Neurology, 1988
- Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell linesActa Neuropathologica, 1988
- Toxicity of ligand and antibody‐directed ricin A‐chain conjugates recognizing the epidermal growth factor receptorJournal of Cellular Physiology, 1987
- Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cellsJournal of Neuroscience Research, 1982
- Penetration of Brain and Brain Tumor. VII. Tumor-Binding Sulfhydryl Boron CompoundsJournal of Medicinal Chemistry, 1967